Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience
M Merli, M Accorinti, M Romagnuolo, A Marzano… - Frontiers in …, 2023 - frontiersin.org
Cutaneous immune-related adverse events are frequently associated with immune
checkpoint inhibitors (ICIs) administration in cancer patients. In fact, these monoclonal …
checkpoint inhibitors (ICIs) administration in cancer patients. In fact, these monoclonal …
Cutaneous adverse reactions of immunotherapy in patients with advanced melanoma
V Nikolaou, A Tsimpidakis, A Stratigos - Cancers, 2023 - mdpi.com
Simple Summary It is estimated that 30–50 percent of patients treated with Immune
Checkpoint Blockers will eventually develop cutaneous immune-related adverse events …
Checkpoint Blockers will eventually develop cutaneous immune-related adverse events …
Immunotherapy for keratinocyte cancers. Part II: Identification and management of cutaneous side effects of immunotherapy treatments
ALS Chang, L Zaba, BY Kwong - Journal of the American Academy of …, 2023 - Elsevier
Keratinocytic cancers (KCs), specifically cutaneous squamous cell and basal cell
carcinomas, can respond to topical, intralesional, or systemic immunotherapies, but …
carcinomas, can respond to topical, intralesional, or systemic immunotherapies, but …
Diagnostic accuracy of general dermatologists and supportive oncodermatologists for biopsied cutaneous immune-related adverse events
LL Thompson, JT Said, EB Li, J Yoon… - Supportive Care in …, 2022 - Springer
Purpose Supportive oncodermatology has been shown to improve several aspects of care
for patients with cancer, but research showing improved diagnostic accuracy as a benefit of …
for patients with cancer, but research showing improved diagnostic accuracy as a benefit of …
Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study
A Luangnara, S Kiratikanon, T Ketpueak… - Frontiers in …, 2022 - frontiersin.org
Background Although immune checkpoint inhibitors (ICIs) have become the frontline
treatment option for patients with various advanced cancers due to improved survival, they …
treatment option for patients with various advanced cancers due to improved survival, they …
Dermatological autoimmune considerations of immune checkpoint therapy
The most common immune-related adverse events (irAEs) involve the skin, and several
serve as predictors of response to immune checkpoint inhibitor (ICI) therapy, especially in …
serve as predictors of response to immune checkpoint inhibitor (ICI) therapy, especially in …
Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large …
RM Reardon, KL Perlman, MS Asdourian… - Journal of the American …, 2024 - Elsevier
To the Editor: Among patients with cancer receiving immune checkpoint inhibitor (ICI)
therapy, dermatologic immune-related adverse events (D-irAEs) are the earliest arising and …
therapy, dermatologic immune-related adverse events (D-irAEs) are the earliest arising and …
[HTML][HTML] Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
P Duraisamy, VV Panicker, WM Jose - Dermatology Practical & …, 2023 - ncbi.nlm.nih.gov
Objectives To study the various cIRAEs in Indian patients on ICI therapy and to analyze the
association between cIRAEs and patient survival outcomes. Methods We conducted a …
association between cIRAEs and patient survival outcomes. Methods We conducted a …